Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

被引：16

作者：

Goel, Shom ^{[1
]}

Tan, Antoinette R. ^{[2
]}

Rugo, Hope S. ^{[3
]}

Aftimos, Philippe ^{[4
]}

Andric, Zoran ^{[5
]}

Beelen, Andrew ^{[6
]}

Zhang, Jingshan ^{[6
]}

Yi, John S. ^{[6
]}

Malik, Rajesh ^{[6
]}

O'Shaughnessy, Joyce ^{[7
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC 28204 USA

[3] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94158 USA

[4] Univ Libre Bruxelles, Inst Jules Bordet, B-1070 Brussels, Belgium

[5] Clin Hosp Ctr Bezanijska Kosa, Belgrade 11080, Serbia

[6] G1 Therapeut, Res Triangle Pk, NC 27709 USA

[7] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX 75246 USA

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 33期

关键词：

carboplatin; CDK4/6; inhibitor; gemcitabine; immunotherapy; metastatic; overall survival; patient-reported outcome; phase III; trilaciclib; triple-negative breast cancer; DOUBLE-BLIND; SURVIVAL; CHEMOTHERAPY; WOMEN; FULVESTRANT;

D O I：

10.2217/fon-2022-0773

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor that induces transient cell cycle arrest of hematopoietic stern and progenitor cells and immune cells during chemotherapy exposure, protecting them from chemotherapy-induced damage and enhancing immune activity. Administration of trilaciclib prior to gemcitabine plus carboplatin (GCb) significantly improved overall survival (OS) compared with GCb alone in an open-label phase II trial in patients with metastatic TNBC, potentially through protection and direct activation of immune function. The randomized, doubleblind, placebo-controlled, phase III PRESERVE 2 trial will evaluate the efficacy and safety of trilaciclib administered prior to GCb in patients with locally advanced unresectable or metastatic TNBC.

引用

页码：3701 / 3711

页数：11

共 38 条

[1] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[2] Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium [J].

Chollet-Hinton, Lynn ;

Olshan, Andrew F. ;

Nichols, Hazel B. ;

Anders, Carey K. ;

Lund, Jennifer L. ;

Allott, Emma H. ;

Bethea, Traci N. ;

Hong, Chi -Chen ;

Cohen, Stephanie M. ;

Khoury, Thaer ;

Zirpoli, Gary R. ;

Borges, Virginia F. ;

Rosenbergs, Lynn A. ;

Bandera, Elisa V. ;

Ambrosone, Christine B. ;

Palmers, Julie R. ;

Troester, Melissa A. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (12) :1722-1729

[3] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC [J].

Cortes, J. ;

Cescon, D. W. ;

Rugo, H. S. ;

Im, S-A. ;

Yusof, M. Md ;

Gallardo, C. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez-Garcia, J. ;

Iwata, H. ;

Masuda, N. ;

Otero, M. Torregroza ;

Gokmen, E. ;

Loi, S. ;

Guo, Z. ;

Zhou, X. ;

Karantza, V. ;

Pan, W. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2021, 32 :S1289-S1290

[4]

Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

[5]

Cristofanilli M., 2022, CLIN CANCER RES, V28, P3433

[6] Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial [J].

Daniel, Davey ;

Kuchava, Vladimer ;

Bondarenko, Igor ;

Ivashchuk, Oleksandr ;

Reddy, Sreekanth ;

Jaal, Jana ;

Kudaba, Iveta ;

Hart, Lowell ;

Matitashvili, Amiran ;

Pritchett, Yili ;

Morris, Shannon R. ;

Sorrentino, Jessica A. ;

Antal, Joyce M. ;

Goldschmidt, Jerome .

INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) :2557-2570

[7] Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed [J].

den Brok, Wendie D. ;

Speers, Caroline H. ;

Gondara, Lovedeep ;

Baxter, Emily ;

Tyldesley, Scott K. ;

Lohrisch, Caroline A. .

BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) :549-556

[8] CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation [J].

Deng, Jiehui ;

Wang, Eric S. ;

Jenkins, Russell W. ;

Li, Shuai ;

Dries, Ruben ;

Yates, Kathleen ;

Chhabra, Sandeep ;

Huang, Wei ;

Liu, Hongye ;

Aref, Amir R. ;

Ivanova, Elena ;

Paweletz, Cloud P. ;

Bowden, Michaela ;

Zhou, Chensheng W. ;

Herter-Sprie, Grit S. ;

Sorrentino, Jessica A. ;

Bisi, John E. ;

Lizotte, Patrick H. ;

Merlino, Ashley A. ;

Quinn, Max M. ;

Bufe, Lauren E. ;

Yang, Annan ;

Zhang, Yanxi ;

Zhang, Hua ;

Gao, Peng ;

Chen, Ting ;

Cavanaugh, Megan E. ;

Rode, Amanda J. ;

Haines, Eric ;

Roberts, Patrick J. ;

Strum, Jay C. ;

Richards, William G. ;

Lorch, Jochen H. ;

Parangi, Sareh ;

Gunda, Viswanath ;

Boland, Genevieve M. ;

Bueno, Raphael ;

Palakurthi, Sangeetha ;

Freeman, Gordon J. ;

Ritz, Jerome ;

Haining, W. Nicholas ;

Sharpless, Norman E. ;

Arthanari, Haribabu ;

Shapiro, Geoffrey I. ;

Barbie, David A. ;

Gray, Nathanael S. ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2018, 8 (02) :216-233

[9] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis [J].

Emens, L. A. ;

Adams, S. ;

Barrios, C. H. ;

Dieras, V ;

Iwata, H. ;

Loi, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Winer, E. P. ;

Patel, S. ;

Henschel, V ;

Swat, A. ;

Kaul, M. ;

Molinero, L. ;

Patel, S. ;

Chui, S. Y. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2021, 32 (08) :983-993

[10] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study [J].

Emens, Leisha A. ;

Molinero, Luciana ;

Loi, Sherene ;

Rugo, Hope S. ;

Schneeweiss, Andreas ;

Dieras, Veronique ;

Iwata, Hiroji ;

Barrios, Carlos H. ;

Nechaeva, Marina ;

Anh Nguyen-Duc ;

Chui, Stephen Y. ;

Husain, Amreen ;

Winer, Eric P. ;

Adams, Sylvia ;

Schmid, Peter .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08) :1005-1016

← 1 2 3 4 →